1/12/2018: Click webinar image to learn more and register for the 1/19/18 Webinar:
2/2/2017: Lantheus Medical Imaging Announces FDA Approval of DEFINITY® Label Update
1/11/2017: The FDA removes the contraindication for use of Bracco Diagnostics Inc.’s LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use, in patients with cardiac shunts
1/12/2017: Bracco Diagnostics Inc.’s LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use, receives U.S. Food and Drug Administration approval for use in ultrasonography of the urinary tract in pediatric patients for the evaluation of suspected or known vesicoureteral reflux
4/16/2016: First Approval by U.S. Food and Drug Administration for Contrast Enhanced Ultrasonography of the Liver
M. Beth McCarville, MD, Chair Susan J. Back, MD, Vice Chair Patricia T. Acharya, MD Carol E. Barnewolt, MD Joo Y. Cho, MD Kassa Darge, MD, PhD, Advisory Reza Daugherty, MD Lynn A. Fordham, MD, FACR Ami Gokli, MD Preetam Gongidi, DO Misun Hwang, MD Jeannie K. Kwon, MD Annie Lim, DO Martha M. Munden, MD Harriet J. Paltiel, MD Judy H. Squires, MD Abhay S. Srinivasan, MD
5th International Pediatric CEUS Course June 24th and 25th, 2019 King’s College Hospital in London Draft Program
More information to come!
06/16/2014: Editorial: Sellars ME, Deganello A, Sidhu PS. Paediatric Contrast-Enhanced Ultrasound (CEUS): A Technique that Requires Co-operation for Rapid Implementation into Clinical Practice. Ultraschall in Med 2014; 35: 203-206
SPR CEUS Task Force Guidelines for Intravenous Administration of Ultrasound Contrast Agents
SPR CEUS Task Force Guidelines for Contrast-enhanced voiding urosongraphy (ceVUS)
Pediatr Radiol. 2014 Nov;44(11):1478-84. doi: 10.1007/s00247-014-3135-5. Epub 2014 Oct 21. ESPR uroradiology task force imaging recommendations in paediatric uroradiology, part VII: standardised terminology, impact of existing recommendations, and update on contrast-enhanced ultrasound of the paediatric urogenital tract. Riccabona M1, Vivier PH, Ntoulia A, Darge K, Avni F, Papadopoulou F, Damasio B, Ording-Muller LS, Blickman J, Lobo ML, Willi U; ESPR Uroradiology Task Force.
Radiology. 2011 May;259(2):614-5; author reply 615. doi: 10.1148/radiol.11102479. Voiding urosonography: an additional important indication for use of US contrast agents. Darge K.
Publications of interest:
Ultrasound Med Biol. 2015 Apr;41(4):1095-9. doi: 10.1016/j.ultrasmedbio.2014.11.003. Epub 2015 Feb 18. Safety of intravenous application of second-generation ultrasound contrast agent in children: prospective analysis. Piskunowicz M1, Kosiak W2, Batko T2, Piankowski A3, Połczyńska K2, Adamkiewicz-Drożyńska E2.
Pediatr Radiol. 2014 Jun;44(6):719-28. doi: 10.1007/s00247-013-2832-9. Epub 2014 Jan 18. Contrast-enhanced voiding urosonography with intravesical administration of a second-generation ultrasound contrast agent for diagnosis of vesicoureteral reflux: prospective evaluation of contrast safety in 1,010 children. Papadopoulou F1, Ntoulia A, Siomou E, Darge K.
Am J Cardiol. 2013 Oct 1;112(7):1039-45. doi: 10.1016/j.amjcard.2013.05.042. Epub 2013 Jun 28. Safety of ultrasound contrast agents in patients with known or suspected cardiac shunts. Parker JM1, Weller MW, Feinstein LM, Adams RJ, Main ML, Grayburn PA, Cosgrove DO, Goldberg BA, Darge K,Nihoyannopoulos P, Wilson S, Monaghan M, Piscaglia F, Fowlkes B, Mathias W, Moriyasu F, Chammas MC, Greenbaum L,Feinstein SB.
Pediatr Radiol. 2013 Sep;43(9):1063-73. doi: 10.1007/s00247-013-2746-6. Epub 2013 Jul 11. Safety of contrast-enhanced ultrasound in children for non-cardiac applications: a review by the Society for Pediatric Radiology (SPR) and the International Contrast Ultrasound Society (ICUS). Darge K1, Papadopoulou F, Ntoulia A, Bulas DI, Coley BD, Fordham LA, Paltiel HJ, McCarville B, Volberg FM, Cosgrove DO,Goldberg BB, Wilson SR, Feinstein SB.
Expert Opin Drug Saf. 2009 Jan;8(1):49-56. doi: 10.1517/14740330802658581 . Ultrasound contrast agents: balancing safety versus efficacy. Main ML1, Goldman JH, Grayburn PA.
Ultrasound Med Biol. 2006 Sep;32(9):1369-75. The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations. Piscaglia F1, Bolondi L; Italian Society for Ultrasound in Medicine and Biology (SIUMB) Study Group on Ultrasound Contrast Agents.
Lumason Reimbursement information (from Bracco)
Download PDF here.
Currently Available Coding for contrast enhanced liver ultrasound:
Lumason benefits from a pass-through code and that means reimbursement is available for the contrast agent for patients in the outpatient settings. The code is Q9950. Lumason is the only contrast agent with this coverage, coding and reimbursement.
2016
Nemours Children's Hospital Orlando, Florida
2017 AIUM meeting
Submit abstracts by September 28
Start planning today!
Meet the 2016 AIUM Award Winners
Downloadable Spreadsheet - Publications 2014-2016
Downloadable spreadsheet - Publications from 2013 and before
Link to PDF of Package Insert/Prescribing Information
GE Healthcare Announces FDA Labeling Change for Use of OPTISON™ in Patients with Cardiac Shunts
Link to PDF Package Insert
Lantheus Medical Imaging Announces FDA Approval of DEFINITY® Label Update
Content coming...
Answers to Committee Questions - click here
Dr Paul Sidhu, Dr Maria Sellars, and Dr Annamaria Deganello at Kings College Hospital, London
Child with Focal Nodular Hyperplasia, with early enhancement, demonstration of central scar, and prolonged enhancement, effectively excluding malignancy.
@Carmina Duran. MD. UDIAT-SDI, Corporació Sanitària i Universitària Parc Taulí, Sabadell, Spain.
Urethra Normal
Posterior urethral valve
ceVUS video clip shoing vesicoureteral reflux, with a normal urethra on transperineal voiding images
@Beth McCarville, MD
Contrast Enhanced CT shows Liver Metastasis from Transitional Cell Carcinoma in a 16 year old boy.
Non-Contrast Enhanced Sagittal Ultrasound Image using Contrast Specific Software. Background tissue appears blue.
Early Arterial Phae after IV administration of a perflutren contrast agent. The contrast agent appears orange. The liver metastasis shows enhancement during this phase.
Portal-venous phase shows washout of contrast from the metastasis, a feature typical of malignant liver lesions.
@Kassa Darge, MD, PhD
CEUS with the bladder full of microbubbles and refluxing into the right ureter. Clear depiction of a right vesicoureteric reflux. No reflux on the left. Contrast specific technique with color overlay and subtraction makes the reflux detection much easier
CEUS with microbubbles in the right renal pelvis which is not markedly dilated. Contrast specific technique with color overlay and subtraction makes the reflux detection much easier
Contrast-enhanced image with color overlay showing reflux, with grey scale subtracted.
CeVUS - Liver Laceration & Kidney Perfusion Defect Not Seen On Grey-Scale Ultrasound
@Doris Franke, MD - Medizinische Hochschule Hannover
Small hematoma in hepato-renal space
Y-Shaped liver laceration and major perfusion defect lower pole, right kidney